Companies › Dianthus Therapeutics
1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Claseprubart complement C5 inhibitor | FCER2, COMP | Phase 3 | Myasthenia Gravis, Generalized; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06537999 | Claseprubart | Phase 2 | Multifocal Motor Neuropathy | Neurology | Dec 2026 |
| NCT06282159 | Claseprubart | Phase 2 | Myasthenia Gravis, Generalized | Neurology | Oct 2028 |
| NCT07647510 | Claseprubart | Phase 3 | Myasthenia Gravis, Generalized | Neurology | Dec 2028 |
| NCT06858579 | Claseprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Dec 2028 |
Held by 17 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Tiziana Life Sciences Abcuro Keros Therapeutics Acumen Pharmaceuticals Vor Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.